Additionally, the 36-month beta value for LAB is 1.30. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for LAB is 367.76M and currently, short sellers hold a 4.39% ratio of that float. The average trading volume of LAB on July 03, 2025 was 1.75M shares.
LAB) stock’s latest price update
The stock price of Standard BioTools Inc (NASDAQ: LAB) has surged by 6.20% when compared to previous closing price of $1.29, but the company has seen a 9.60% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-23 that Combines highly complementary proteomics expertise with Illumina’s industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market Illumina and SomaLogic have partnered in proteomics co-development since late 2021 SAN DIEGO, June 23, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) announced today it has entered into a definitive agreement with Standard BioTools (NASDAQ: LAB) under which Illumina will acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance-based milestones and performance-based royalties. “The acquisition of SomaLogic will enhance Illumina’s presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024.
LAB’s Market Performance
LAB’s stock has risen by 9.60% in the past week, with a monthly rise of 30.48% and a quarterly rise of 25.69%. The volatility ratio for the week is 9.42% while the volatility levels for the last 30 days are 8.62% for Standard BioTools Inc The simple moving average for the past 20 days is 20.42% for LAB’s stock, with a -8.21% simple moving average for the past 200 days.
Analysts’ Opinion of LAB
TD Cowen, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.50. The rating they have provided for LAB stocks is “Buy” according to the report published on April 16th, 2024.
Jefferies gave a rating of “Buy” to LAB, setting the target price at $3.25 in the report published on April 04th of the previous year.
LAB Trading at 23.08% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.15% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Kim Hanjoon Alex, who sale 1,428 shares at the price of $0.94 back on May 23 ’25. After this action, Kim Hanjoon Alex now owns 930,286 shares of Standard BioTools Inc, valued at $1,344 using the latest closing price.
Mackay Sean, the SVP & Chief Business Officer of Standard BioTools Inc, sale 13,217 shares at $0.94 during a trade that took place back on May 23 ’25, which means that Mackay Sean is holding 843,076 shares at $12,437 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.47 for the gross margin
The net margin for Standard BioTools Inc stands at -0.78. The total capital return value is set at -0.27. Equity return is now at value -25.73, with -19.56 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -3.53. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -42.04.
Currently, EBITDA for the company is -118.14 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 2.36. The receivables turnover for the company is 4.78for trailing twelve months and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.12.
Conclusion
In conclusion, Standard BioTools Inc (LAB) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
